Ani Pharmaceuticals (ANIP)
NASDAQ:ANIP
Want to see ANIP full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.02Last Year’s EPS
1.8Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and material financial progress: consolidated Q1 revenue growth (20% YoY), Cortrophin Gel growth (42% YoY), adjusted EBITDA and EPS expansion, raised 2026 guidance, near-term cash from an IP out-license, an active product launch cadence in Generics, and a sizeable commercial expansion into acute gouty arthritis flares. Offsetting items include margin pressure from a higher mix of royalty-bearing products and new launches, temporary insurance reverification and access headwinds that impacted Q1 timing, increased SG&A from sales expansion, and some reliance on timing of upfront/milestone payments. Overall, positives (revenue/EBITDA growth, guidance raise, strategic investments and M&A optionality, cash position, repurchase program) materially outweigh the lowlights (margin compression, access and timing issues), supporting a constructive outlook for 2026 and into 2027.Company Guidance
Revenue Growth and Raised Guidance
Total net revenues of $237.5M in Q1 2026, up 20% year-over-year. Company raised 2026 net revenue guidance to $1.08B–$1.14B (midpoint implies ~26% growth vs 2025) and expects Rare Disease to represent ~60% of total revenues in 2026.
Cortrophin Gel Strong Performance
Cortrophin Gel net revenues of $75.1M in Q1, up 42% year-over-year and in line with expectations; management expects Cortrophin Gel revenues of $540M–$575M in 2026 (guidance implies ~60% YoY growth) and reported highest new patient starts and monthly volumes in April since launch.
Expanded Rare Disease Commercial Investment
Accelerated commercial expansion into acute gouty arthritis flares via a dedicated organization (company cited a ~90-person expansion and referenced adding 64 new sales reps), targeting ~7,000 HCPs; expecting this expansion to begin contributing late Q2 and materially in H2 2026 and into 2027.
Adjusted EBITDA and EPS Improvement
Adjusted non-GAAP EBITDA of $63.0M in Q1, up 24% year-over-year. Adjusted non-GAAP diluted EPS of $2.05 vs $1.70 prior year (up ~20.6%). Full-year adjusted EBITDA guidance raised to $285M–$300M (up $10M from prior guide) and adjusted EPS guidance set to $9.19–$9.69.
Generics and Product Launch Progress
Generics revenues of $105.4M in Q1, up 7% year-over-year; year-to-date launch of 6 new generics and maintaining cadence of 10–15 launches annually. Company remains #2 in overall CGT approvals.
Strategic IP Licensing with Near-Term Cash
Out-licensing transaction with Harmony recognized $21.5M of associated revenues in Q1 (including $15M upfront license fee and initial royalties). Potential additional $10M in development milestones expected in Q2–Q3 2026 plus low single-digit royalties on pitolisant-based products; Harmony guidance implies WAKIX net revenues of $1B–$1.04B in 2026.
Operational Cash and Balance Sheet Position
Unrestricted cash at quarter end $311.2M (up $25.6M vs Dec 31, 2025). Cash flow from operations of $58.4M in Q1. Net leverage 1.3x and gross leverage 2.6x on trailing 12-month adjusted EBITDA of $242M, providing capacity for BD and buybacks.
Capital Allocation Actions
Board authorized a new $100M share repurchase program (3-year) and reaffirmed disciplined capital allocation with focus on BD and organic investments supporting Rare Disease growth.
ILUVIEN Commercial Progress and Data Generation
ILUVIEN revenues of $19.3M in Q1, up 20% YoY. Published NEW DAY DME results in Ophthalmology and on track to present SYNCHRONICITY Phase IV results in NIU-PS at a medical meeting in Q3 2026, supporting long-term addressable opportunity expansion.
ANIP Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ANIP Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2026 | $83.91 | $81.86 | -2.44% |
Mar 03, 2026 | $75.22 | $76.10 | +1.17% |
Nov 10, 2025 | $90.43 | $88.93 | -1.66% |
Aug 08, 2025 | $69.01 | $81.48 | +18.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Ani Pharmaceuticals (ANIP) report earnings?
Ani Pharmaceuticals (ANIP) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is Ani Pharmaceuticals (ANIP) earnings time?
Ani Pharmaceuticals (ANIP) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ANIP EPS forecast?
ANIP EPS forecast for the fiscal quarter 2026 (Q2) is 2.02.